



ASX Announcement

MARCH 2020 QUARTERLY UPDATE AND APPENDIX 4C

29 April 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) today releases its Appendix 4C Quarterly Cash Flow Report for the period ended 31 March 2020 and provides an update on financial and operational performance.

During the quarter ended 31 March 2020 (Q1 2020) net cash outflows from operating activities were US\$3.010 million. Receipts from customers during the period were US\$0.198 million comprising of a payment for an MR EP Recorder/Stimulator System. Payments made in relation to operating costs of US\$3.208 million were up from the prior quarter due to increased staffing costs as Imricor expanded its workforce across multiple functional areas as well as increased administration costs related to legal, accounting and the timing of annual licences.

Net cash outflows from investing activities were US\$0.210 million during Q1 2020. Net cash inflows from financing activities were US\$12.610 million in the period, largely comprising net proceeds from the institutional placement completed in February 2020.

At 31 March 2020, Imricor maintained a cash balance of US\$13.303 million.

Imricor's Chair and CEO, Steve Wedan said "We began our commercial launch in the first quarter, and while we were affected by the coronavirus pandemic mid-quarter, we were extremely pleased with the early success of procedures undertaken at the Dresden Heart Centre, highlighting the effectiveness of Active Catheter Imaging. We are excited and well prepared to continue the clinical rollout once hospital operations begin to normalise."

Annual meeting of stockholders

Imricor will hold its annual meeting of stockholders on Wednesday, 13 May 2020 at 9:00am Sydney time or Tuesday, 12 May 2020 at 6:00pm US Central Daylight Time. Due to restrictions on travel and public gatherings associated with COVID-19 this will be held as a virtual meeting and will include the facility for investors to ask questions during the meeting. Further information on participating at the meeting is included in the proxy statement dispatched to investors and in the virtual meeting guide available on Imricor's website at <https://imricor.com/investors/>.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS



Further Information

Investors:

Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028

Media:

Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor expects to sell its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

For personal use only



Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only

Annexure

The quarter ended 31 March 2020 is a period covered by the Uses of Funds statement as outlined in Imricor's prospectus dated 14 August 2019. A summary of expenditure to date is outlined below:

| Use of funds | Prospectus dated 14 August 2019 & Pre-Quotation Disclosure released at the time of admission (US\$m) | Actual Expenditure since admission on 30 August 2019 to 31 March 2020 (US\$m) |
|--------------------------------------|--|---|
| Sales and marketing | 1.475 | 0.474 |
| Clinical and regulatory | 5.418 | 2.122 |
| Costs of the Combined Offers | 1.198 | 1.325 |
| Other working capital ^(a) | 1.536 | 2.082 |
| All other ^(a) | - | 2.907 |
| Total | 9.627 | 8.910 |

- (a) Actual expenditure exceeds prospectus expectations as the prospectus anticipated that revenue from the commercialisation of Imricor's products would be used to fund other working capital as well as investments in inventory and operations, capital equipment and repayment of debt. This revenue was however not realised due to the delay in CE Mark approval and subsequent delay in commercial launch due to COVID-19.

Payment made to related parties as described in item 6.1 on the Appendix 4C were for director fees.

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Imricor Medical Systems, Inc.

ABN

633 106 019

Quarter ended ("current quarter")

31 March 2020

| Consolidated statement of cash flows | Current quarter \$USD'000 | Year to date (3 months) \$USD'000 |
|---|--------------------------------------|--|
| 1. Cash flows from operating activities | | |
| 1.1 Receipts from customers | 198 | 198 |
| 1.2 Payments for | | |
| (a) research and development | (251) | (251) |
| (b) product manufacturing and operating costs | (681) | (681) |
| (c) advertising and marketing | (73) | (73) |
| (d) leased assets | - | - |
| (e) staff costs | (1,409) | (1,409) |
| (f) administration and corporate costs | (716) | (716) |
| 1.3 Dividends received (see note 3) | - | - |
| 1.4 Interest received | 1 | 1 |
| 1.5 Interest and other costs of finance paid | (79) | (79) |
| 1.6 Income taxes paid | - | - |
| 1.7 Government grants and tax incentives | - | - |
| 1.8 Other (provide details if material) | - | - |
| 1.9 Net cash from / (used in) operating activities | (3,010) | (3,010) |
| 2. Cash flows from investing activities | | |
| 2.1 Payments to acquire: | | |
| (a) entities | - | - |
| (b) businesses | - | - |
| (c) property, plant and equipment | (126) | (126) |
| (d) investments | - | - |
| (e) intellectual property | (55) | (55) |
| (f) other non-current assets | (29) | (29) |

For personal use only

| Consolidated statement of cash flows | | Current quarter \$USD'000 | Year to date (3 months) \$USD'000 |
|--------------------------------------|---|------------------------------|---|
| 2.2 | Proceeds from disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | - |
| | (d) investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other (provide details if material) | - | - |
| 2.6 | Net cash from / (used in) investing activities | (210) | (210) |

| | | | |
|-------------|---|---------------|---------------|
| 3. | Cash flows from financing activities | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | 13,407 | 13,407 |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | (709) | (709) |
| 3.5 | Proceeds from borrowings | - | - |
| 3.6 | Repayment of borrowings | (88) | (88) |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other (provide details if material) | - | - |
| 3.10 | Net cash from / (used in) financing activities | 12,610 | 12,610 |

| | | | |
|-----------|--|---------|---------|
| 4. | Net increase / (decrease) in cash and cash equivalents for the period | | |
| 4.1 | Cash and cash equivalents at beginning of period | 5,049 | 5,049 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (3,010) | (3,010) |
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (210) | (210) |

| Consolidated statement of cash flows | | Current quarter \$USD'000 | Year to date (3 months) \$USD'000 |
|--------------------------------------|---|------------------------------|---|
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | 12,610 | 12,610 |
| 4.5 | Effect of movement in exchange rates on cash held | (1,136) | (1,136) |
| 4.6 | Cash and cash equivalents at end of period | 13,303 | 13,303 |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter \$USD'000 | Previous quarter \$USD'000 |
|-----|---|------------------------------|-------------------------------|
| 5.1 | Bank balances | 13,303 | 13,303 |
| 5.2 | Call deposits | - | - |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 13,303 | 13,303 |

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$USD'000**

100

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

| | Total facility amount at quarter end \$USD'000 | Amount drawn at quarter end \$USD'000 |
|---------------------------------------|---|--|
| 7.1 Loan facilities | - | - |
| 7.2 Credit standby arrangements | - | - |
| 7.3 Other (please specify) | - | - |
| 7.4 Total financing facilities | - | - |

7.5 **Unused financing facilities available at quarter end** -

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

| 8. Estimated cash available for future operating activities | \$USD'000 |
|---|------------------|
| 8.1 Net cash from / (used in) operating activities (Item 1.9) | (3,010) |
| 8.2 Cash and cash equivalents at quarter end (Item 4.6) | 13,303 |
| 8.3 Unused finance facilities available at quarter end (Item 7.5) | - |
| 8.4 Total available funding (Item 8.2 + Item 8.3) | 13,303 |
| 8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1) | 4.4 |

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2020

Authorised by: the Audit and Risk Committee
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.